To compare measured IFX concentrations in our laboratory with values predicted by iDose dashboard system and report its efficacy in managing patients not responding to conventional dosing schedule.


 Clinical history, demographic details, and laboratory findings such as albumin and C-reactive protein (CRP) data of IBD patients (n = 30; median age 23 years (IQR: 14.25 - 33.5)) referred for IFX drug monitoring in our laboratory from November 2017 to November 2019 were entered in iDose software.  The IFX concentration predicted by iDose based on this information was compared with that measured in our laboratory.  The iDose predicted concentration showed concordance in 21 of these 30 patients.  Of 11 patients managed with iDose-assisted prospective dosing, 8 achieved clinical remission, 2 showed partial response, and one developed antibodies.


 Retrospective data analysis showed concordance between laboratory measured and iDose-predicted IFX level in 70% of patients.  iDose-assisted management achieved clinical remission and cost reduction.
iDose
Clinical history, demographic details, and laboratory findings such as albumin and C-reactive protein (CRP) data of IBD patients (n = 30; median age 23 years (IQR: 14.25 - 33.5)) referred for IFX drug monitoring in our laboratory from November 2017 to November 2019 were entered in iDose software. 
iDose software